Transgender Women's Experiences Using a Home HIV-Testing Kit for Partner-Testing.


Journal

AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 21 3 2020
medline: 21 8 2020
entrez: 21 3 2020
Statut: ppublish

Résumé

HIV partner-testing (PT) may represent a unique and empowering HIV prevention strategy for groups that face structural and institutional barriers to HIV testing and care, including transgender women. We report on in-depth interviews (IDIs) with N = 10 transgender women who used HIV self-test kits for three months to screen potential sexual partners in a randomized controlled trial (iSUM; "I'll Show You Mine") that took place in New York City and San Juan, Puerto Rico. Participants were assigned to intervention (supplied with 10 self-test kits immediately) or control groups (received 6 test kits after 3 months). We conducted IDIs with the first N = 10 transgender women to enroll in the intervention group after three months in the study (after participants used kits with partners) to understand their experiences. Themes discussed in IDIs included: partners' reaction to HIV testing, participants' reactions to partners' test results or refusal to test, partners' own reaction to their test results, and decision-making around test use. Data were independently analyzed by two coders. Overwhelmingly, participants' experiences with PT was positive. Participants reported kits were convenient and acceptable to most partners. Transgender women felt that PT could pose additional risk for them; one woman experienced violence related to kit use. Furthermore, the availability of kits appeared to encourage participants and their partners to think about their HIV status and, in some cases, modify sexual behavior. Work suggests that HIV PT could be a viable risk-reduction strategy for transgender women.

Identifiants

pubmed: 32193729
doi: 10.1007/s10461-020-02829-x
pii: 10.1007/s10461-020-02829-x
pmc: PMC7725406
mid: NIHMS1581819
doi:

Substances chimiques

Reagent Kits, Diagnostic 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2732-2741

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR001870
Pays : United States
Organisme : NLM NIH HHS
ID : T15 LM007079
Pays : United States
Organisme : AHRQ HHS
ID : K12 HS026383
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH043520
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069415
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD076636
Pays : United States
Organisme : NIMHD NIH HHS
ID : P60 MD006902
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI113127
Pays : United States
Organisme : NLM NIH HHS
ID : R01 LM013045
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH43520
Pays : United States
Organisme : NLM NIH HHS
ID : R01 LM012355
Pays : United States
Organisme : NIMH NIH HHS
ID : K01 MH115785
Pays : United States
Organisme : National Institute of Child Health and Human Development
ID : R01 AI113127

Références

AIDS Behav. 2012 Jan;16(1):1-4
pubmed: 21476006
AIDS Behav. 2009 Aug;13(4):731-7
pubmed: 19415483
AIDS Behav. 2018 Jan;22(1):347-357
pubmed: 29124420
PLoS Med. 2011 Nov;8(11):e1001124
pubmed: 22131907
AIDS Behav. 2012 Oct;16(7):1753-60
pubmed: 22893194
AIDS Behav. 2020 Feb;24(2):506-515
pubmed: 31865516
PLoS One. 2018 Jun 20;13(6):e0198606
pubmed: 29924873
Lancet Infect Dis. 2013 Mar;13(3):214-22
pubmed: 23260128
BMC Public Health. 2013 Aug 08;13:735
pubmed: 23924387
Mhealth. 2019 Jun 18;5:17
pubmed: 31380409
Health Care Women Int. 2014;35(7-9):703-27
pubmed: 24564483
AIDS Behav. 2020 Jun;24(6):1929-1941
pubmed: 31853772
Int J STD AIDS. 2017 Nov;28(13):1341-1347
pubmed: 28449628
AIDS Behav. 2018 Nov;22(11):3627-3636
pubmed: 29589137
PLoS One. 2017 Mar 27;12(3):e0174629
pubmed: 28346527
Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):168-71
pubmed: 26910276
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
J Sex Res. 2012;49(4):379-87
pubmed: 22293029
Lancet HIV. 2016 Jun;3(6):e266-74
pubmed: 27240789
AIDS Behav. 2016 Apr;20(4):928-38
pubmed: 26511864
Lancet HIV. 2015 Dec;2(12):e512-9
pubmed: 26614965
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25251
pubmed: 30907508

Auteurs

Christine Tagliaferri Rael (CT)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA. Cr2857@cumc.columbia.edu.

Rebecca Giguere (R)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.

Javier Lopez-Rios (J)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.

Cody Lentz (C)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.

Iván C Balán (IC)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.

Alan Sheinfil (A)

Department of Psychology, Syracuse University, Syracuse, NY, USA.

Curtis Dolezal (C)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.

William Brown (W)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.
Department of Medicine, Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA, USA.
Division of General Internal Medicine, Department of Medicine, School of Medicine, Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, CA, USA.
Baker Computational Health Science Institute, University of California San Francisco, San Francisco, CA, USA.

Timothy Frasca (T)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.

Catherine Cruz Torres (CC)

Department of Pediatrics, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA.

Raynier Crespo (R)

Division of General Internal Medicine, Department of Medicine, School of Medicine, Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, CA, USA.

Sarah Iribarren (S)

School of Nursing, University of Washington, Seattle, WA, USA.

Cheng-Shiun Leu (CS)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.

Irma Febo (I)

Department of Pediatrics, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA.

Alex Carballo-Diéguez (A)

HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University, 1051 Riverside Dr, New York, NY, 10032, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH